ClinicalTrials.gg
RecruitingNCT07021638EMMVIESUpdated Dec 31, 2025

EMMVIES : Walking Training at Home in VIrtual Reality for Children With Chronic Illnesses Impacting Physical Health

An interventional study of EMMVIES program in Home-based Programs, EzyGain and AMY Treadmill, sponsored by University Hospital, Angers. Recruiting at 1 site in France. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Cerebral Palsy with a site in France — 29 open to participants now, 30 under way, none of them phase 3. Cerebral Palsy · France.

Planned enrollment
35th of 59
30 · median 36
Started
2025
with 6 others
No phase
48 of 91
20 open now
Primary completion
2027-12
later than 16 of 29 live
Registered
75th of 91
by date

Among the 91 studies in Cerebral Palsy with a site in France, this one is the 35th largest by planned enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2025, is one of 48 with no phase, reaches primary completion later than 16 of the 29 other live ones, and was the 75th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

29 of the 91 studies in Cerebral Palsy with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Cerebral Palsy with a site in France, or all of them as a file.
02

Study summary

Over the past 30 years, the prevalence of congenital or acquired chronic diseases in children has risen, affecting between 10 and 30% of them, or at least 100,000 children in France. Pathologies such as cerebral palsy (CP), neuromuscular diseases (NMD), obesity or congenital heart disease impact physical health by causing musculoskeletal, respiratory or cardiovascular deficiencies. These limitations influence their ability to participate in daily activities, affecting their quality of life and that of their families.To minimize these impacts, motor rehabilitation programs focusing on physical activity are proposed, but their effectiveness requires prolonged practice. However, these specific programs, often delivered in remote specialized centers, are difficult to access. Home programs have been developed to overcome these constraints. They enable children, with the support of their parents, to carry out therapeutic activities at home. Although their feasibility has been demonstrated, their effectiveness is relative. A multitude of protocols and tools have been tested, with no harmonization of practices.To support the implementation of home-based programs for children with CP or obesity, virtual reality has already been used, mainly on the basis of commercial solutions. This solution is therefore feasible and has proved relatively effective.With this in mind, and based on the user experience of children, parents and professionals, the investigators have initially co-developed with the French company EzyGain a connected treadmill specifically adapted to pediatric needs and the requirements of home programs. The AMY treadmill is a compact treadmill with on-board sensors and a safety system, communicating with a tablet application and a virtual reality headset.Taking into account the opportunities offered by this new technology, as well as building on the effects and features already known from home programs, the investigators have developed a new modality for home programs focusing on walking for children with CP, MNM and obesity, the EMMVIES program. The crucial step now is to investigate the feasibility, tolerance and clinical effects of this EMMVIES program.

03

Conditions studied

  • Home-based Programs
  • EzyGain
  • AMY Treadmill
  • Cerebral Palsy
  • Neuromuscular Diseases (NMD)
  • Obesity
  • Virtual Reality
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 6 to 17 years at date of inclusion;
  • Able to walk for 5 minutes on a treadmill with or without body weight support, with or without technical aids;
  • Be able to understand and play virtual reality games (immersive or non-immersive);
  • Be able to answer questionnaires;
  • Patient affiliated to or benefiting from a social security scheme;
  • , dated and signed by parents or guardians (if minors), to participate in the study;
  • Included in a care program specific to their chronic condition for at least 6 months;
  • Meet the following criteria depending on the group:

PC group:

  • Diagnosis of CP
  • Functional level classified II or III according to the Gross Motor Function Classification System (GMFCS)
  • Rehabilitation goal: improvement of gait and/or gross motor function

OB group:

  • Overweight or obese, defined by a above the IOTF-25 percentile
  • Aim to increase daily physical activity
  • No history of hip pathology

Group NM:

  • Diagnosis of one of the following neuromuscular pathologies: spinal muscular atrophy type 3, Duchenne disease, congenital myopathy or Charcot Marie Tooth.
  • Functional level of grade 2 to 6 on the Walton scale, or grade 3 to 7 on the Vignos scale
  • Rehabilitation goal: improvement of walking and/or gross motor skills

Exclusion criteria

Exclusion Criteria:

  • Patients weighing over 100 kg (due to the technical constraints of using the AMY mat).
  • For children aged 6 to 11: in connection with the immersive virtual reality device: problems with stereoscopic vision (perception of images in 3 dimensions), unstabilized epilepsy, facial trauma \< 3 months, hearing or visual impairment, pain, dizziness or nausea caused by using immersive virtual reality.
  • Patients who have undergone surgery in the last 3 months;
  • Patients who have received intramuscular botulinum toxin injections in the lower limbs or intensive therapy in the 3 months prior to inclusion;
  • Patient with a non-routine therapeutic program planned within 5 months that could lead to confusion with the tested program;
  • Patient with insufficient understanding of the French language;
  • Patient opposition (child or adolescent);
  • Persons deprived of liberty by judicial or administrative decision;
  • Persons under compulsory psychiatric care;
  • Persons under legal protection;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    EMMVIES program

    Evaluate the feasibility of the home training program.

    Other: EMMVIES program

Interventions

  • OtherEMMVIES program

    Walking Training at Home in VIrtual Reality for Children with Chronic Illnesses Impacting Physical Health

06

What researchers measure

Primary outcomes

  1. Home rehabilitation program

    The treadmill walking training program comprises a minimum of 3 sessions per week, with one day of rest between each session. Each session comprises around 30 minutes of physical exercise on a mat, alternating between walking and balance exercises.

    Time frame: 3 x 30-minute sessions over 10 weeks

Secondary outcomes

  1. Assessment of lower limb muscle strength

    Muscle strength is measured using a wireless electronic hand dynamometer (DEM) (MicroFET 2) based on a standardized protocol used in clinical routine and performed on an examination table on the following muscle groups: plantar flexors (knee extended and flexed), knee flexors and extensors and hip abductors. The child is asked to contract each muscle group tested for 3 to 5 seconds, three times against the dynamometer held by an assessor. The average of the three peak pressures achieved for each muscle group tested is recorded. The estimated duration of these measurements is 15 minutes.

    Time frame: Inclusion, 10 weeks and 20 weeks

  2. 10-meter walk test

    Patients' gait quality is assessed using a minimal version of the Quantified Gait Analysis (QGA), which simply includes spatiotemporal, kinematic and electromyographic gait parameters. To this end, 10-meter barefoot walking tests at spontaneous (2 trials), fast (2 trials) and double-task speeds, i.e. walking and listing animal names (1 trial) and fruit names (1 trial), and finally with usual shoes and orthoses, are carried out. Walking tests are performed in comfortable clothing, as close to the body as possible, with uncovered legs (shorts). A walking frame is authorized for children who cannot walk 10 meters without one. The total duration of the assessment for the child is 20 minutes.

    Time frame: Inclusion, 10 weeks and 20 weeks

  3. 6-minute walk test

    Walking endurance is assessed by the 6-minute walking test (TDM6). According to the instructions for this test, the distance covered in 6 minutes is observed. Children are asked to walk as far as possible in 6 minutes on a 60-meter marked track in corridors. Children are fitted with shoes, orthoses and/or walking aids, depending on their habits. Footwear and technical aids must be identical between the 3 evaluation times T0, T1 and T2. An indication of the remaining test time is given to the children every minute by the investigator. The duration of the test for the child is estimated at 10 minutes.

    Time frame: Inclusion, 10 weeks and 20 weeks

  4. Motion control assessment

    Somatosensory function is measured by the cortico-cinematic coherence (CKC) index, which reflects the correlation between electrical activity in the primary sensorimotor cortex (measured by conventional low-density electroencephalogram (EEG)) and displacement of the center of pressure (CoP) in standing static equilibrium for 2 minutes (measured by a force platform). This exploratory index will enable us to estimate the cortical processing of proprioceptive afferents in the lower limbs. The estimated duration of this measurement is 10 minutes.

    Time frame: Inclusion, 10 weeks and 20 weeks

  5. Balance assessment

    Balance is assessed by 30-second unipodal hold tests (1 trial), if possible for the child, and 30-second bipodal hold tests under open-eye (1 trial), closed-eye (1 trial), foam (1 trial) and double-task conditions, i.e. counting backwards from 50 (1 trial). These tests are performed on a force platform (AMTI Accusway) to record the CoP's trajectory. The evaluation is scheduled to last 10 minutes.

    Time frame: Inclusion, 10 weeks and 20 weeks

  6. Assessment of gross motor functions for children with CP

    The GMFM-66 is a 66-item quantitative observational scale for assessing gross motor function in children with cerebral palsy (CP). Five dimensions of gross motor function are tested: Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing, Dimension E: walking, running and jumping. Each item is scored on a 4-point scale, depending on whether the task requested by the investigator has been completed in full or in part. A maximum of three trials is allowed, and any spontaneous performance is accepted. The GMFM 66 takes around 45 minutes to complete.

    Time frame: Inclusion, 10 weeks and 20 weeks

  7. Assessment of gross motor functions for children with MNM

    For children with neuromuscular disorders (NMD), the Motor Function Measure (MFM). The MFM is a quantitative observational scale comprising 32 items, divided into 3 domains: domain D1: standing and transfer, domain D2: axial and proximal function, and domain D3: distal function. Each item assesses a specific motor task, and performance is rated on a scale from 0 to 3. The child is asked to perform the various MFM tasks. The MFM takes around 45 minutes to complete.

    Time frame: Inclusion, 10 weeks and 20 weeks

  8. Quality of life assessment

    Quality of life is assessed by the KIDSCREEN questionnaire. The KIDSCREEN-27 measures health-related quality of life in children and adolescents aged 8 to 18, across five dimensions: physical well-being, psychological well-being, autonomy and relationships with parents, social support and relationships with peers, and school environment. In this study, only the dimensions of physical well-being, psychological well-being, autonomy and relationships with parents are assessed. The questionnaire is completed by the child, unless under 8 years of age. Approximate completion time for children is 5 minutes.

    Time frame: Inclusion, 10 weeks and 20 weeks

  9. Assessment of daily activities and mobility

    Achievement of daily activities and mobility is assessed by the Pediatric Evaluation of Disability Inventory as a Computer Adaptive Test (PEDI-CAT). The PEDI-CAT measures the functional abilities of children with disabilities in four functional domains: activities of daily living, mobility, social and cognitive activities, and responsibility. The daily activities and mobility domains are assessed. The questionnaire is completed online during the consultation by the child accompanied by at least one parent. It takes approximately 15 minutes for the child to complete the questionnaire online.

    Time frame: Inclusion, 10 weeks and 20 weeks

  10. Actimetry

    Daily physical activity (PA) is measured using an actimeter (Actigraph GT3X). The following parameters are observed: number of daily steps, time spent at different levels of phsyical activity intensity (sedentary, light, moderate to vigorous), and time spent in different positions (lying, sitting, standing). The actimeter is worn on a belt during the day and on the wrist at night, for 7 consecutive days before or after each visit.

    Time frame: Inclusion, 10 weeks and 20 weeks

  11. User experience - User Experience Questionnaire

    The short version of the User Experience Questionnaire (UEQ-S) is used. It contains 8 items grouped into two scales: pragmatic qualities (efficiency, insight, reliability) and hedonic qualities (stimulation, novelty). The format of the items is a semantic differential (e.g. Complicated - Simple) with a 7-point Likert scale. This questionnaire was chosen because it is the most widely used in the literature and has already been used with children.

    Time frame: once at 20 weeks

  12. User experience - Usability Metric for User Experience

    The Usability Metric for User Experience (UMUX) is a short 4-item questionnaire. The items are statements about ease of use and usefulness, with which respondents express agreement on a 7-point Likert scale. The UMUX is strongly correlated with the System Usability Scale (SUS), which is the most widely used usability questionnaire, with a large amount of associated research literature, but contains 10 items. The scores obtained on the UMUX are therefore used to position the solution's usability on the SUS interpretation scale ("worst imaginable", "poor", "acceptable", "good", 'excellent' or "best imaginable").

    Time frame: once at 20 weeks

  13. User experience - Mobile Applications Rating Scale version utilisateur

    The MARS (Mobile Applications Rating Scale user version) comprises 23 items divided into 6 domains. We will examine the first 3 domains: engagement, functionality and aesthetics. Answers are given on 5-point Likert scales.

    Time frame: once at 20 weeks

07

Study locations

1 of 1 sites recruiting
  • Les Capucins
    Angers, France
    Recruiting
    • Mickaël DINOMAIS, MD · ContactMickael.Dinomais@chu-angers.fr · + 33 2 41 35 52 67
    • Adélie CHRISTIAENS, MD · Principal investigator
    • Fabienn EMERIAU, MD · Principal investigator
    • Julien DURIGNEUX, MD · Principal investigator
    • Marion BEAUMESNIL, MD · Principal investigator
    • Anthony COEHLO, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 23 months is above that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 15, 2025
StartActual
Dec 24, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021638
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Dec 24, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Mickaël DINOMAIS, MD
Contact
Mickael.Dinomais@chu-angers.fr
+ 33 2 41 35 52 67 ext. + 33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion